The global community is facing a number of urgent challenges, such as emerging diseases, epidemics, antimicrobial resistance, ...
Data from Catalent’s preclinical studies evaluating certepetide as a SMARTag® ADC payload showed both improved tumor selective penetration and efficacy BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE ...
The surge in AI and digital infrastructure is making data centers the fastest-growing source of new electricity demand in ...
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies.In vivo, CTX-10726 outperformed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results